Sharp, Alexandra M.
Lertphinyowong, Suphada
Yee, Samantha S.
Paredes, Denisse
Gelfond, Jonathan
Johnson-Pais, Teresa L.
Leach, Robin J.
Liss, Michael
Risinger, April L.
Sullivan, Anna C.
Thompson, Ian M.
Morilak, David A. http://orcid.org/0000-0001-6689-6258
Funding for this research was provided by:
Cancer Prevention and Research Institute of Texas (RP180055)
National Institutes of Health, National Cancer Institute (CA224672)
Mays Cancer Center, UT Health San Antonio
National Cancer Institute (P30 CA054174)
Article History
Received: 21 December 2018
Accepted: 10 May 2019
First Online: 28 May 2019
Compliance with ethical standards
: All research procedures were reviewed and approved by the Institutional Animal Care and Use Committee (IACUC) of the University of Texas Health, San Antonio, and are compliant with the ethical standards of the National Institutes of Health as specified in the Guide for the Care and Use of Laboratory Animals.
: Vortioxetine was provided by H. Lundbeck A/S, which had no input into the conduct of the study, analysis or interpretation of the data, and no role in the decision to publish or in the writing of the manuscript. Dr. Morilak receives research funding from Alkermes that has no relation to the present work. All other authors declare that they have no conflicts of interest.